Bedrijfsoverzicht
Artivion, Inc. is a global manufacturer and distributor specializing in medical devices and implantable human tissues, with its core product portfolio including On-X prosthetic aortic and mitral heart valves, ascending aortic prosthesis, CarbonAid CO2 diffusion catheters, Chord-X ePTFE sutures, and pyrolytic carbon coatings. Operating within the Healthcare sector as a Medical Devices company, the firm addresses critical needs in cardiovascular interventions and tissue engineering solutions. The enterprise operates at a significant scale, evidenced by a market capitalization of $1.82 billion, annual revenue of $441.33 million, and an employee base of 1,800 individuals. These financial dimensions indicate that Artivion is an established mid-to-large-cap entity within its niche, possessing the infrastructure and human capital necessary for global distribution and manufacturing of complex implantable technologies.
Financiële gezondheid
The company reported revenue of $441.33 million over the trailing twelve months, generating net income of $9.76 million and EBITDA of $53.80 million during the same period. The substantial disparity between the $441.33 million in revenue and the $9.76 million in net income reveals a cost structure where operating expenses and taxes consume the majority of top-line growth, resulting in a profit margin of 2.2%. While the EBITDA stands at $53.80 million, the free cash flow is reported at -$20,097,624, which indicates that capital expenditures or working capital requirements currently exceed operational cash generation, limiting immediate financial flexibility for share buybacks or aggressive debt reduction without external financing. The gross margin stands at 64.4%, reflecting the high value added by manufacturing specialized implantable tissues and devices. The operating margin of 8.1% suggests that while the core business is profitable, significant overheads related to research, development, and global logistics are impacting bottom-line efficiency. The profit margin of 2.2% highlights the aggressive nature of the competitive medical device market or high R&D investment relative to current earnings. On the balance sheet, the company holds $64.91 million in cash against $258.51 million in debt, resulting in a debt-to-equity ratio of 57.67, which characterizes a highly leveraged financial position. Despite the leverage, a current ratio of 3.53 demonstrates robust short-term liquidity, indicating that the firm can easily meet its obligations due to strong current assets relative to current liabilities. Return on equity is calculated at 2.7%, while return on assets sits at 2.3%, metrics that collectively reveal management is currently utilizing shareholder capital and asset base with modest efficiency, a common trait for capital-intensive medical device firms in growth phases.
Waarderingsbeoordeling
The valuation metrics present a distinct picture, with a trailing P/E ratio of 179.19 compared to a forward P/E of 32.55. This significant divergence between the high trailing multiple and the much lower forward multiple implies that the market expects a substantial improvement in earnings trajectory, suggesting that current earnings are anomalously low or that future growth is anticipated to be robust enough to justify a multiple contraction. The price-to-book ratio is recorded at 4.02, indicating that the stock trades at a substantial premium over its book value, which often reflects investor confidence in the intangible value of the company's intellectual property and market position. Alternative valuation measures further contextualize the stock's price; the price-to-sales ratio stands at 4.14, while the EV/EBITDA is 37.09, suggesting that the market is pricing in high future growth expectations rather than current profitability. In terms of trading range, the stock has a 52-week high of $48.25 and a 52-week low of $22.22, meaning the current market price sits significantly below the recent peak but well above the trough. The beta value is 1.62, which signifies that the stock exhibits high volatility and is expected to move with greater amplitude than the broader market index.
Growth & Income
Revenue growth over the year-on-year period is recorded at 19.2%, while earnings growth is listed as N/A, indicating that the company is currently unable to report comparable earnings growth rates, likely due to the low base effect of recent net income or one-time charges impacting the calculation. The absence of earnings growth data relative to the strong 19.2% revenue expansion implies that the top-line growth has not yet fully translated into bottom-line gains, a typical dynamic for companies in the early stages of a new product cycle or restructuring. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute cash to shareholders, meaning all free cash flow is retained to fund operations, debt repayment, or reinvestment into research and development. Consequently, Artivion's overall growth and income profile is characterized by aggressive revenue expansion and a zero-dividend policy that prioritizes internal capital generation over immediate shareholder returns, reflecting a strategy focused on long-term market penetration and product innovation within the medical device sector.